Transcranial photobiomodulation (light therapy) for children and teens with ADHD
Official title: An Intervention Study on Transcranial Photobiomodulation for Children With Attention-Deficit/Hyperactivity Disorder
Run by Qilu Hospital of Shandong University · NCT06685601 · Data updated 2026-11-12
This will test whether a noninvasive head-light treatment called transcranial photobiomodulation can improve attention and executive skills in children and adolescents with ADHD.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 6 Years to 18 Years |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | Qilu Hospital of Shandong University Academic / other |
| Locations | 2 sites (Jinan, Shandong and 1 other locations) |
| Status | Recruiting |
| Started | December 16, 2024 |
| Main results expected | November 2026 |
| Study ends | May 2027 |
| Registry record updated | July 22, 2025 |
| Trial ID | NCT06685601 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are children and adolescents aged 6–18 with a primary DSM-5 diagnosis of ADHD, no other psychiatric comorbidities, and the ability to cooperate with the procedure and attend in-person visits with parental consent.
✕Probably not a fit
Children with other psychiatric disorders, serious medical or neurologic conditions (for example epilepsy), sensory impairments, or those unable to cooperate with the procedures are unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a randomized, triple-blind, within-subject trial in which each participant receives one active and one sham transcranial photobiomodulation (tPBM) session in counterbalanced order with at least one week between sessions. Standardized clinical ratings and parent reports are collected at baseline and immediately after each session, while objective measures of executive function are gathered using cognitive tests, EEG, and eye tracking. Trained technicians deliver the interventions according to randomization while both participants and clinical evaluators remain blinded. The goal is to compare active versus sham stimulation effects to identify the most effective acute stimulation strategy for pediatric ADHD.
Why it matters
Potential benefit: If successful, tPBM could offer a noninvasive, drug-free option to improve attention and executive function in children with ADHD.
How similar studies have gone: Small pilot studies and early work with tPBM have reported some cognitive and neurophysiologic changes, but robust randomized controlled evidence in pediatric ADHD remains limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age between 6 and 18 years; 2. Clinically diagnosed with ADHD by a psychiatrist; 3. Confirmed by the researcher (child psychiatrist) to meet the diagnostic criteria for Attention-Deficit/Hyperactivity Disorder as outlined in the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5); 4. M.I.N.I. KID interview shows only ADHD, with no other comorbidities; 5. Able to cooperate with transcranial photobiomodulation. 6. The participant and their guardian fully understand the study procedures and content and agree to participate in the study, signing the informed consent form. Exclusion Criteria: 1. Diagnosis of other severe mental illnesses, such as schizophrenia or bipolar disorder; 2. Presence of severe physical diseases or conditions, such as significant intracranial lesions, thyroid disorders, epilepsy, congenital heart disease, severe hematologic disorders, systemic lupus erythematosus, auditory or visual impairments, etc.; 3. Presence of significant structural brain abnormalities on imaging studies; 4. Presence of severe neurological diseases with a clear family history or potential risk; 5. Presence of metal implants or a pacemaker, or holes or fractures in the skull; 6. Currently undergoing other ADHD treatments (e.g., methylphenidate or other pharmacological treatments, behavioral therapy, etc.) or has discontinued such treatments for less than 2 weeks; 7. Raven's Progressive Matrices IQ score \< 85.
Where it's running
-
Qilu Hospital of Shandong University
Jinan, Shandong, China Recruiting -
Qilu Hospital of Shandong University
Jinan, Shandong, China Not yet recruiting
Study contacts
- Study coordinator: Aihua Cao, Post-doctoral
- Email: xinercah@163.com
- Phone: 18560086317
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
AI-assisted home-based mood diary for kids with ADHD
A home-based program uses an AI-assisted diary that turns daily mood entries into comic strips to see if it helps kids with ADHD improve emotion regulation.
-
Medication effects on eye movements and autonomic function in children and teens with ADHD
This study tests how ADHD medication influences eye movements and autonomic nervous system signals in kids and teens with ADHD.
-
Medication treatment for ADHD in children with epilepsy
This study tests whether a stimulant medicine (Jornay PM) helps ADHD symptoms in children who also have epilepsy.
-
Retail-grade weighted blanket for sleep in children with ADHD
This study tests whether using a retail-grade weighted blanket for 4 weeks helps children with ADHD sleep better.
-
MOCHA: Inpatient Mental Health Care for High-Risk Pregnancy
This study tests a collaborative mental health program for pregnant or recently postpartum patients hospitalized for medical problems to see if it can be delivered feasibly and acceptably.
-
ADRIS 2.1 driving simulator for adolescents with ADHD.
This project will test whether the ADRIS 2.1 driving simulator can measure and train driving-related skills in adolescents aged 13–18 with ADHD.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.